U.S. Food and Drug Administration main campus building. Photo: ALM.
As the U.S. is seeking to sever ties with some Chinese biotech players, a bipartisan group of lawmakers on Tuesday called on the Biden administration to ramp up scrutiny of hundreds of clinical trials conducted by U.S. drug companies with the Chinese military, citing the risk of intellectual property theft, as the nations compete on biotechnology.
Rep. John Moolenaar (R-MI), who chairs the House Select Committee on China, and ranking Rep. Raja Krishnamoorthi (D-IL) said U.S. drug companies have collaborated with Chinese military-run hospitals to conduct hundreds of clinical trials over the last decade, including in Xinjiang, home to millions of ethnic minorities where the Chines government has launched a campaign of human rights abuses.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
